Increased risk of secondary leukemia after single-agent treatment with etoposide for langerhans' cell hlstlocytosls

Riccardo Haupt; Thomas R. Fears; Paolo Rosso; Roberto Colella; Ciuseppe Loiacono; Marino de Terlizzi; Antonia Mancini; Adele Comelli; Paolo Indolfi; Alberto Donfrancesco; Patrizia Operamolla; Giuseppe Graria; Adriana Ceci; Margaret A. Tucker

doi:10.3109/08880019409141688

Increased risk of secondary leukemia after single-agent treatment with etoposide for langerhans' cell hlstlocytosls

Riccardo Haupt, Thomas R. Fears, Paolo Rosso, Roberto Colella, Ciuseppe Loiacono, Marino de Terlizzi, Antonia Mancini, Adele Comelli, Paolo Indolfi, Alberto Donfrancesco, Patrizia Operamolla, Giuseppe Graria, Adriana Ceci, Margaret A. Tucker

Istituto "Giannina Gaslini"

Research output: Contribution to journal › Article › peer-review

Abstract

The study evaluated 139 patients diagnosed with Langerhans' cell histiocytosis (LCH) and enrolled in any protocol of the Italian Association of Pediatric Hematology/Oncology since 1982, Treatment was etoposide (VP-16) only in 50 patients, VP-16 and other drugs with an already established bukemogenic effect in 17 patients, only drugs with leukemogenic effect in 6 patients, other drugs in 35 patients, and surgery only in 31 patients. Median length of follow-up after diagnosis was 65 months (range, 1 to 126 months) for a total of 742.5 person-years at risk (PYRs). Three cases of acute myelogenous leukemia (AML) were reported; only 0.0044 case was expected. The standard incidence ratio (SIR) of AML in this cohort was 680.5 [95% confidence interval (CI), 140.2-1988.5], and the incidence rate per 1000 PYRs was 4.0 (95% CI, 0.8-11.8). For the subgroup treated with single-agent VP-16, the SIR after treatment was 2270.0 (95% CI, 275-8199), and the incidence rate after treatment was 14.7 (95% CI, 1.8-42.8). The study confirms a higher risk of leukemia after LCH and supports the hypothesis of an association between treatment-related acute nonlymphocytic leukemia and single-agent treatment with VP-16.

Original language	English
Pages (from-to)	499-507
Number of pages	9
Journal	Pediatric Hematology and Oncology
Volume	11
Issue number	5
DOIs	https://doi.org/10.3109/08880019409141688
Publication status	Published - 1994

Keywords

Etoposide
Langerhans' cell histiocytosis
Late effects
Secondary leukemia

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health
Hematology
Oncology
Cancer Research
Management of Technology and Innovation

Access to Document

10.3109/08880019409141688

Fingerprint Dive into the research topics of 'Increased risk of secondary leukemia after single-agent treatment with etoposide for langerhans' cell hlstlocytosls'. Together they form a unique fingerprint.

Cite this

Haupt, R., Fears, T. R., Rosso, P., Colella, R., Loiacono, C., de Terlizzi, M., Mancini, A., Comelli, A., Indolfi, P., Donfrancesco, A., Operamolla, P., Graria, G., Ceci, A., & Tucker, M. A. (1994). Increased risk of secondary leukemia after single-agent treatment with etoposide for langerhans' cell hlstlocytosls. Pediatric Hematology and Oncology, 11(5), 499-507. https://doi.org/10.3109/08880019409141688

Increased risk of secondary leukemia after single-agent treatment with etoposide for langerhans' cell hlstlocytosls. / Haupt, Riccardo; Fears, Thomas R.; Rosso, Paolo; Colella, Roberto; Loiacono, Ciuseppe; de Terlizzi, Marino; Mancini, Antonia; Comelli, Adele; Indolfi, Paolo; Donfrancesco, Alberto; Operamolla, Patrizia; Graria, Giuseppe; Ceci, Adriana; Tucker, Margaret A.

In: Pediatric Hematology and Oncology, Vol. 11, No. 5, 1994, p. 499-507.

Research output: Contribution to journal › Article › peer-review

Haupt, R, Fears, TR, Rosso, P, Colella, R, Loiacono, C, de Terlizzi, M, Mancini, A, Comelli, A, Indolfi, P, Donfrancesco, A, Operamolla, P, Graria, G, Ceci, A & Tucker, MA 1994, 'Increased risk of secondary leukemia after single-agent treatment with etoposide for langerhans' cell hlstlocytosls', Pediatric Hematology and Oncology, vol. 11, no. 5, pp. 499-507. https://doi.org/10.3109/08880019409141688

Haupt, Riccardo ; Fears, Thomas R. ; Rosso, Paolo ; Colella, Roberto ; Loiacono, Ciuseppe ; de Terlizzi, Marino ; Mancini, Antonia ; Comelli, Adele ; Indolfi, Paolo ; Donfrancesco, Alberto ; Operamolla, Patrizia ; Graria, Giuseppe ; Ceci, Adriana ; Tucker, Margaret A. / Increased risk of secondary leukemia after single-agent treatment with etoposide for langerhans' cell hlstlocytosls. In: Pediatric Hematology and Oncology. 1994 ; Vol. 11, No. 5. pp. 499-507.

@article{00d5b4f5dbf749a1a47b4a03ca5f16aa,

title = "Increased risk of secondary leukemia after single-agent treatment with etoposide for langerhans' cell hlstlocytosls",

abstract = "The study evaluated 139 patients diagnosed with Langerhans' cell histiocytosis (LCH) and enrolled in any protocol of the Italian Association of Pediatric Hematology/Oncology since 1982, Treatment was etoposide (VP-16) only in 50 patients, VP-16 and other drugs with an already established bukemogenic effect in 17 patients, only drugs with leukemogenic effect in 6 patients, other drugs in 35 patients, and surgery only in 31 patients. Median length of follow-up after diagnosis was 65 months (range, 1 to 126 months) for a total of 742.5 person-years at risk (PYRs). Three cases of acute myelogenous leukemia (AML) were reported; only 0.0044 case was expected. The standard incidence ratio (SIR) of AML in this cohort was 680.5 [95% confidence interval (CI), 140.2-1988.5], and the incidence rate per 1000 PYRs was 4.0 (95% CI, 0.8-11.8). For the subgroup treated with single-agent VP-16, the SIR after treatment was 2270.0 (95% CI, 275-8199), and the incidence rate after treatment was 14.7 (95% CI, 1.8-42.8). The study confirms a higher risk of leukemia after LCH and supports the hypothesis of an association between treatment-related acute nonlymphocytic leukemia and single-agent treatment with VP-16.",

keywords = "Etoposide, Langerhans' cell histiocytosis, Late effects, Secondary leukemia",

author = "Riccardo Haupt and Fears, {Thomas R.} and Paolo Rosso and Roberto Colella and Ciuseppe Loiacono and {de Terlizzi}, Marino and Antonia Mancini and Adele Comelli and Paolo Indolfi and Alberto Donfrancesco and Patrizia Operamolla and Giuseppe Graria and Adriana Ceci and Tucker, {Margaret A.}",

year = "1994",

doi = "10.3109/08880019409141688",

language = "English",

volume = "11",

pages = "499--507",

journal = "Pediatric Hematology and Oncology",

issn = "0888-0018",

publisher = "Informa Healthcare",

number = "5",

}

TY - JOUR

T1 - Increased risk of secondary leukemia after single-agent treatment with etoposide for langerhans' cell hlstlocytosls

AU - Haupt, Riccardo

AU - Fears, Thomas R.

AU - Rosso, Paolo

AU - Colella, Roberto

AU - Loiacono, Ciuseppe

AU - de Terlizzi, Marino

AU - Mancini, Antonia

AU - Comelli, Adele

AU - Indolfi, Paolo

AU - Donfrancesco, Alberto

AU - Operamolla, Patrizia

AU - Graria, Giuseppe

AU - Ceci, Adriana

AU - Tucker, Margaret A.

PY - 1994

Y1 - 1994

N2 - The study evaluated 139 patients diagnosed with Langerhans' cell histiocytosis (LCH) and enrolled in any protocol of the Italian Association of Pediatric Hematology/Oncology since 1982, Treatment was etoposide (VP-16) only in 50 patients, VP-16 and other drugs with an already established bukemogenic effect in 17 patients, only drugs with leukemogenic effect in 6 patients, other drugs in 35 patients, and surgery only in 31 patients. Median length of follow-up after diagnosis was 65 months (range, 1 to 126 months) for a total of 742.5 person-years at risk (PYRs). Three cases of acute myelogenous leukemia (AML) were reported; only 0.0044 case was expected. The standard incidence ratio (SIR) of AML in this cohort was 680.5 [95% confidence interval (CI), 140.2-1988.5], and the incidence rate per 1000 PYRs was 4.0 (95% CI, 0.8-11.8). For the subgroup treated with single-agent VP-16, the SIR after treatment was 2270.0 (95% CI, 275-8199), and the incidence rate after treatment was 14.7 (95% CI, 1.8-42.8). The study confirms a higher risk of leukemia after LCH and supports the hypothesis of an association between treatment-related acute nonlymphocytic leukemia and single-agent treatment with VP-16.

AB - The study evaluated 139 patients diagnosed with Langerhans' cell histiocytosis (LCH) and enrolled in any protocol of the Italian Association of Pediatric Hematology/Oncology since 1982, Treatment was etoposide (VP-16) only in 50 patients, VP-16 and other drugs with an already established bukemogenic effect in 17 patients, only drugs with leukemogenic effect in 6 patients, other drugs in 35 patients, and surgery only in 31 patients. Median length of follow-up after diagnosis was 65 months (range, 1 to 126 months) for a total of 742.5 person-years at risk (PYRs). Three cases of acute myelogenous leukemia (AML) were reported; only 0.0044 case was expected. The standard incidence ratio (SIR) of AML in this cohort was 680.5 [95% confidence interval (CI), 140.2-1988.5], and the incidence rate per 1000 PYRs was 4.0 (95% CI, 0.8-11.8). For the subgroup treated with single-agent VP-16, the SIR after treatment was 2270.0 (95% CI, 275-8199), and the incidence rate after treatment was 14.7 (95% CI, 1.8-42.8). The study confirms a higher risk of leukemia after LCH and supports the hypothesis of an association between treatment-related acute nonlymphocytic leukemia and single-agent treatment with VP-16.

KW - Etoposide

KW - Langerhans' cell histiocytosis

KW - Late effects

KW - Secondary leukemia

UR - http://www.scopus.com/inward/record.url?scp=0028018901&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028018901&partnerID=8YFLogxK

U2 - 10.3109/08880019409141688

DO - 10.3109/08880019409141688

M3 - Article

C2 - 7826846

AN - SCOPUS:0028018901

VL - 11

SP - 499

EP - 507

JO - Pediatric Hematology and Oncology

JF - Pediatric Hematology and Oncology

SN - 0888-0018

IS - 5

ER -